BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is trading at $65.56, about ₹6,295 at today's USD/INR rate, as of 25 Sep 2026, 2:03 PM ET, down 1.09% today. Indian residents can buy BridgeBio Pharma from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$64.84
Today's high
$67.07
52 week low
$48.88
52 week high
$93.42
BBIO opened at $66.72, closed previously at $66.28, and has traded between $48.88 and $93.42 over the past 52 weeks.
About
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Key statistics
Avg. volume
3.03M
Market cap
$12.84B
P/E Ratio
-18.31
Price-to-sales ratio
18.56
Enterprise value
$14.66B
Free cash flow yield
-4.61%
Debt-to-equity ratio
-0.99
Return on equity
31.67%
ROIC
-61.77%
Beta
0.97
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$502.08M
Earnings per share
-$3.79
Free cash flow
-$447.01M
Net profit margin
-100.64%
Gross margin
93.14%
EBITDA
-$672.88M
Revenue growth
126.26%
Similar securities
This is not an investment recommendation
How to buy BridgeBio Pharma from India
Indian residents can buy BridgeBio Pharma shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for BridgeBio Pharma and place an order
Find BridgeBio Pharma by name or by its ticker, BBIO, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. BridgeBio Pharma trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your BridgeBio Pharma position in USD and INR. BridgeBio Pharma pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in BridgeBio Pharma from India
Trading and taxes when buying BridgeBio Pharma from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneBridgeBio Pharma does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy BridgeBio Pharma stock?
Yes. BridgeBio Pharma (BBIO) has been listed on NASDAQ since 2019, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one BridgeBio Pharma share cost in rupees?
One BridgeBio Pharma share is $65.56 — about ₹6,295 at a USD/INR rate of 96.02 on 24 Sep 2026. Both the BridgeBio Pharma price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying BridgeBio Pharma from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of BridgeBio Pharma?
Yes. One BridgeBio Pharma share is $65.56, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in BridgeBio Pharma.
How are gains on BridgeBio Pharma shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the BridgeBio Pharma price. Paasa issues a capital-gains statement for your return.
Does BridgeBio Pharma pay a dividend?
No. BridgeBio Pharma does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade BridgeBio Pharma from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on BridgeBio Pharma shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare BridgeBio Pharma shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your BridgeBio Pharma holding, its cost and its closing value.
How do I sell BridgeBio Pharma and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.